169.38
+1.83(+1.09%)
Currency In USD
| Previous Close | 167.55 |
| Open | 168.56 |
| Day High | 173.78 |
| Day Low | 168.51 |
| 52-Week High | 184.4 |
| 52-Week Low | 80.98 |
| Volume | 772,933 |
| Average Volume | 604,603 |
| Market Cap | 8.54B |
| PE | -36.27 |
| EPS | -4.67 |
| Moving Average 50 Days | 149.19 |
| Moving Average 200 Days | 121.07 |
| Change | 1.83 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) 10 years ago, it would be worth $14,150.38 as of January 10, 2026 at a share price of $169.38. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $2,173.21 as of January 10, 2026 at a share price of $169.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
GlobeNewswire Inc.
Dec 31, 2025 12:00 PM GMT
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
GlobeNewswire Inc.
Dec 31, 2025 11:55 AM GMT
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) dis
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, No